ArticleCureus2024
Real-World Evidence of the Impact of CanAssist Breast on Physician's Decision About the Use of Adjuvant Chemotherapy in Early Breast Cancer.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Construction of the bromodomain-containing protein-associated prognostic model in triple-negative breast cancer.Cancer cell international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Clinicians use prognostic biomarker/multi-gene-based tests for predicting recurrence in hormone receptor-positive/HER2-negative (HR+/HER2-) early-stage breast cancer (EBC). CanAssist Beast (CAB) uses the expression of five protein biomarkers in combination with tumor-specific parameters such as tumor size, histopathological grade, and lymph node status to predict the risk of distant recurrence within five years of diagnosis for patients with HR+/HER2-, EBC. The current study aimed to evaluate the impact of prognostic tests on adjuvant chemotherapy decisions by assessing the agreement between clinical and CAB risk stratification as low-risk (LR) or high-risk (HR) for distant recurrence. Methods The primary study group included 300 patients with HR+/HER2-, EBC diagnosed between 2016 and 2021. The clinical risk assessment and recommended treatment plan were captured before and after receiving the results for CAB. The risk stratification of patients into CAB LR and HR was obtained. Finally, compliance with CAB was analyzed by assessing the concordance of treatment prescribed with the CAB risk category. Results Before performing the CanAssist Breast test, patients were stratified based on clinicopathological features, with 52% of patients as LR, 21% as HR, and 27% of patients distributed as uncertain/intermediate risk (IR) category. CAB re-stratified the same cohort of patients, 67% as LR and 33% as HR, which was 15% higher than that of clinical LR assessment. The clinical IR category was re-stratified by CAB as 51% LR and 49% HR. Changes in treatment recommendations were seen in both clinical HR and clinical LR groups, which were 87% and 85%, respectively. Conclusions CAB has a significant impact on chemotherapy decisions. CAB provides definite treatment recommendations for patients with clinical intermediate risk. Overall, CAB has changed treatment recommendations in 23% of the cohort and for 88% of clinical IR patients helped physicians make a treatment decision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.